Table 2.

Topotecan Pharmacokinetic Analyses

Variable	No. of Patients
	Cycle 1		Cycle 2
	No.	%	No.	%
Pharmacokinetic studies	31		31
Fixed-dose topotecan*	31		31†
Dosing success	14		12
Dosing failure	17		19
Pharmacokinetic guided dosing‡	17		19
Targeting success	12		14
Targeting failure	5		5
Total successes	26	84	26	84
Dosage to achieve target, mg/m2
Median	1.2		1.3
Range	0.75-2.1		1.2-2.9
Dosage to achieve target, mg/kg
Median	0.06		0.11
Range	0.04-0.1		0.04-0.13

^*Success if target area under the curve of 50 to 70 ng/mL/hr was achieved after protocol-defined dose (cycle 1 or cycle 2) or cycle 1–based pharmacokinetic analysis (cycle 2).

^†Fixed dosage per protocol (n = 11) or dosage based on cycle 1 pharmacokinetic analyses.

^‡Success if target area under the curve of 50 to 70 ng/mL/hr was achieved by pharmacokinetic-guided dosing.